Peginterferon beta-1a

From WikiProjectMed
Jump to navigation Jump to search
Peginterferon beta-1a
Trade namesPlegridy, Plegridy Pen
  • 1-Ether with N-(3-hydroxy-2-methylpropyl)interferon β-1a (human) α-methyl-ω-hydroxy-poly(oxy-1,2-ethanediyl)
Clinical data
Drug classImmunomodulator[1]
Main usesMultiple sclerosis[1]
Side effectsHeadache, muscle pain, flu-like symptoms, fever, weakness, redness, pain or itching at the injection site[2]
  • AU: D[3]
  • US: C (Risk not ruled out)[3]
Routes of
Subcutaneous injection
Typical dose125 ucg[4]
External links
US NLMPeginterferon beta-1a
License data
Legal status
  • US: ℞-only [4]
  • EU: Rx-only [2]
  • In general: ℞ (Prescription only)
Chemical and physical data
FormulaC913H1417N246O256PS7 [C2H4O]n
Molar mass44 000 g·mol−1

Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.[1] It is specifically used for the relapsing forms including clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease.[4] It is given by injection under the skin.[1]

Common side effects include headache, muscle pain, flu-like symptoms, fever, weakness, and redness, pain or itching at the injection site.[2] Other side effects may include liver problems, depression, seizures, heart failure, and anaphylaxis.[1] There are concerns with use in pregnancy.[5] How it works is not entirely clear; however it is believed to suppress the immune system.[2] It is made from interferon beta-1a joined with polyethylene glycol.[2]

Peginterferon beta-1a was approved for medical use in the United States and Europe in 2014.[2][1] In the United States it costs about 7,500 USD for 4 weeks of medication as of 2021.[6] This amount in the United Kingdom costs the NHS about £650.[7]

Medical uses

In the United States peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[4]

In the European Union peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.[2]


It is given at a dose of 125 ucg every two weeks.[4] A smaller dose of 94 ucg may be used for the first two shots.[4]


  1. 1.0 1.1 1.2 1.3 1.4 1.5 "Peginterferon Beta-1a Monograph for Professionals". Retrieved 27 October 2021.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Plegridy EPAR". European Medicines Agency (EMA). Retrieved 24 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. 3.0 3.1 "Peginterferon beta-1a (Plegridy) Use During Pregnancy". 22 July 2019. Retrieved 25 June 2020.
  4. 4.0 4.1 4.2 4.3 4.4 4.5 "Plegridy- peginterferon beta-1a kit Plegridy Pen- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution". DailyMed. 30 March 2020. Retrieved 25 June 2020.
  5. "Peginterferon beta-1a (Plegridy) Use During Pregnancy". Retrieved 27 October 2021.
  6. "Plegridy Prices, Coupons & Patient Assistance Programs". Retrieved 27 October 2021.
  7. BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 897. ISBN 978-0857114105.

External links